Our Neurocognitive specialists provide comprehensive diagnostic and treatment care plans for those experiencing memory loss
On July 2nd, 2024 the FDA granted full traditional approval for Kisunla (Donanemab) which is the second fully FDA approved therapy for Alzheimer’s disease that specifically targets the protein plaque beta-amyloid 42.
The approval of Donanemab has now allowed healthcare providers like neurologists and neurocognitive specialists, to continue to be proactive with treating and slowing the progression of Alzheimer’s disease.
On January 6th, 2023, the FDA granted accelerated approval for Leqembi (Lecanemab) which is the second FDA-approved therapy for Alzheimer’s Disease.
Leqembi (Lecanemab) specifically targets protofibrils which cluster together and forms the protein plaque beta-amyloid 42.
Memory Treatment Centers is now actively infusing Leqembi.